

Electronic Acknowledgement Receipt

EFS ID:	5938417
Application Number:	10502403
International Application Number:	
Confirmation Number:	3497
Title of Invention:	Pharmaceutical composition that is used to control blood glucose in patients with type 2 diabetes
First Named Inventor/Applicant Name:	Jose Manuel Francisco Ochoa
Customer Number:	26111
Filer:	Lori Mau Brandes
Filer Authorized By:	
Attorney Docket Number:	2099.0090000
Receipt Date:	24-AUG-2009
Filing Date:	20-JUN-2005
Time Stamp:	16:50:22
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$310
RAM confirmation Number	4384
Deposit Account	
Authorized User	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)

1	Foreign Reference	FP1WO97017975.pdf	729444 0d18b41e5f1a78a6b9865adfc2e60987354 780e1	no	25
---	-------------------	-------------------	--	----	----

Warnings:

Information:

2	Foreign Reference	FP2WO00040233.pdf	847518 996407c3df6527c401fffb1753a33af1cf7b 14d	no	17
---	-------------------	-------------------	---	----	----

Warnings:

Information:

3	Foreign Reference	FP3WO01032158.pdf	3027168 8a5788f2c49b4fa66b8fd37aa92937f1921ca 7f0	no	76
---	-------------------	-------------------	---	----	----

Warnings:

Information:

4	Foreign Reference	FP4WO03061643.pdf	576734 383b78cac1958955ef91f6329a907e75f1d8 9330	no	16
---	-------------------	-------------------	--	----	----

Warnings:

Information:

5	Foreign Reference	FP5WO04045622.pdf	1960199 e087541729eed279b96bc464d04ffb7decc 9da56	no	38
---	-------------------	-------------------	---	----	----

Warnings:

Information:

6	NPL Documents	NPL1AbbinkDiabetMed2002.pdf	552427 37ddde11c1b8f09e88d405ce8c5de3289be 1641c	no	11
---	---------------	-----------------------------	--	----	----

Warnings:

Information:

7	NPL Documents	NPL2BresslerArchInternMed1997.pdf	1445060 2cad0e09619af840afbdaa5457199ec1ab5e fd4	no	16
---	---------------	-----------------------------------	--	----	----

Warnings:

Information:

8	NPL Documents	NPL3CefaluDiabetolgia1996.pdf	460669 5706fcc1fa1b2a05be6e7ae2a32883db06b 3955c	no	4
---	---------------	-------------------------------	--	----	---

Warnings:

Information:

9	NPL Documents	NPL4CefaluDiabetes1996.pdf	444375 14695031b2fa99e2370b230d560206d7853 d8e51	no	4
---	---------------	----------------------------	--	----	---

Warnings:

Information:

10	NPL Documents	NPL5CharpentierDiabetMed2001.pdf	1002752 ca583f9970237713b4feb90bccf40b208abbfd42	no	10
----	---------------	----------------------------------	---	----	----

Warnings:

Information:

11	NPL Documents	NPL6CrouseCirculation1996.pdf	445744 51ceb6a39ae210569b6082c9c24ac6ff566c9fe1	no	4
----	---------------	-------------------------------	--	----	---

Warnings:

Information:

12	NPL Documents	NPL7DagogoJackArchInternMed1997.pdf	4281112 2440b9858702ae82ae68e04c776e70d3ad6ca702	no	19
----	---------------	-------------------------------------	---	----	----

Warnings:

Information:

13	NPL Documents	NPL8DeFronzoAnnInternMed1999.pdf	3673515 a18733e13ce6984cf72ffd8025eeae468d231b3	no	26
----	---------------	----------------------------------	--	----	----

Warnings:

Information:

14	NPL Documents	NPL11GonzalezOrtizRevistaInvestClinica2004.pdf	600486 4d81a221b491624c19acb2750ba6dd809e82fdcc	no	7
----	---------------	--	--	----	---

Warnings:

Information:

15	NPL Documents	NPL12EnglishTranslationofGonzalezOrtizRevistaInvestClinica2004.pdf	489919 36a8a56dec02fb6d6da7bb3d6aa46be5e68cee9	no	9
----	---------------	--	---	----	---

Warnings:

Information:

16	NPL Documents	NPL13GonzalezOrtizJDiabetCompleto2008.pdf	675006 983c6c5e90bfa5db970d116c9bd0b8be75255ba1	no	4
----	---------------	---	--	----	---

Warnings:

Information:

17	NPL Documents	NPL14GomisEndocrine2000.pdf	737262 6a7e612a57832d1949152be5c4065c103fec045	no	8
----	---------------	-----------------------------	---	----	---

Warnings:

Information:

18	NPL Documents	NPL16Higginbothametal.pdf	290609 09568fafef75f7bb2b8e95d2d059ff47e80a22820	no	5
----	---------------	---------------------------	---	----	---

Warnings:

Information:

19	NPL Documents	NPL17HolsteinDiabetologia2000.pdf	284542 7b6f8e2ff7d8d41b007ee80c5202360d51253b07	no	4
----	---------------	-----------------------------------	--	----	---

Warnings:

Information:

20	NPL Documents	NPL18MullerBiochimicaBiophysicaActa1999.pdf	976556 f63870ddd1516bb3bde2f3d1daac466874e e0b5c	no	13
----	---------------	---	--	----	----

Warnings:

Information:

21	NPL Documents	NPL19RosenstockJSamolsE.pdf	963852 c79cc/ba7dbfe8369a1e179f8d6081e3af39 48b7	no	9
----	---------------	-----------------------------	--	----	---

Warnings:

Information:

22	NPL Documents	NPL20SatoExcerptaMedica1994.pdf	756942 d13ed2e59bf6a55a14e9a6b4f8d83625d21 cfb2a	no	6
----	---------------	---------------------------------	--	----	---

Warnings:

Information:

23	NPL Documents	NPL21ScheenDrugs1998.pdf	2180924 e2eb4280c2de9ec970430995993e31f8264 dc02b	no	15
----	---------------	--------------------------	---	----	----

Warnings:

Information:

24	NPL Documents	NPL22SiftonPhysiciansDeskReference2000.pdf	1027031 2b1f3c1764195efbb948476ec21f586119c6 44dd	no	6
----	---------------	--	---	----	---

Warnings:

Information:

25	NPL Documents	NPL23SonnenbergAnnPharmacotherapy1997.pdf	1216892 3818287be4221ffd7888f12d2702642df11 ee8c8	no	9
----	---------------	---	---	----	---

Warnings:

Information:

26	NPL Documents	NPL24VignerietaL.pdf	1885218 4741fc8cd8424ba132ee2d37a987036d202 f7e72	no	6
----	---------------	----------------------	---	----	---

Warnings:

Information:

27	NPL Documents	NPL25ISRPCTMX020003.pdf	576734 31f557b225bf41dabed258f363bba376ffbd 317c	no	16
----	---------------	-------------------------	--	----	----

Warnings:

Information:

28	NPL Documents	NPL261PERPCTMX020003.pdf	68272 47793818e0fc9813a8b5f8460e5896ab5ec 6b01	no	2
----	---------------	--------------------------	--	----	---

Warnings:
Information:

29	NPL Documents	NPL27DighoreIntJPharmTechRes2009.pdf	236487 4b3f11067c949539b7898067a13a2420255 59829	no	13
----	---------------	--------------------------------------	--	----	----

Warnings:
Information:

30		2099009000IDSfiling.pdf	3136047 147ae4919e196874e743a096ea0c9670194 ae7b6	yes	56
----	--	-------------------------	---	-----	----

Multipart Description/PDF files in .zip description

	Document Description	Start	End
	Miscellaneous Incoming Letter	1	2
	Extension of Time	3	3
	Amendment/Req. Reconsideration-After Non-Final Reject	4	4
	Applicant Arguments/Remarks Made in an Amendment	5	48
	Transmittal Letter	49	52
	Information Disclosure Statement (IDS) Filed (SB/08)	53	56

Warnings:
Information:

31	NPL Documents	2099009000NPL9.pdf	975584 65ebcbffbb69e6b78259475bb3fc0820db3 15225	no	10
----	---------------	--------------------	--	----	----

Warnings:
Information:

32	NPL Documents	2099009000NPL10.pdf	738285 c6875e18754eb5a6e756e4424e5f6f1b5914 bc8	no	8
----	---------------	---------------------	---	----	---

Warnings:
Information:

33	NPL Documents	2099009000NPL15.pdf	829919 bbda39075d03044a63e6d8043cefcf804f76 4c3c	no	11
----	---------------	---------------------	--	----	----

Warnings:
Information:

34	Fee Worksheet (PTO-875)	fee-info.pdf	31807 95796263446ff7d7abcb98a1028a96c4d4ca46f	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			38125091		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p>New Applications Under 35 U.S.C. 111 If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p>National Stage of an International Application under 35 U.S.C. 371 If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p>New International Application Filed with the USPTO as a Receiving Office If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					